Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Robotic vs. open surgical management of ureteroenteric anastomotic strictures: technical modifications to enhance success.

Scherzer ND, Greenberg JW, Shaw EJ, Silberstein JL, Thomas R, Krane LS.

J Robot Surg. 2019 Oct 4. doi: 10.1007/s11701-019-01027-9. [Epub ahead of print]

PMID:
31586270
2.

Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer.

Cao S, Ma T, Ungerleider N, Roberts C, Kobelski M, Jin L, Concha M, Wang X, Baddoo M, Nguyen HM, Corey E, Fazli L, Ledet E, Zhang R, Silberstein JL, Zhang W, Zhang K, Sartor O, Dong X, Flemington EK, Dong Y.

Oncogene. 2019 Nov;38(45):7060-7072. doi: 10.1038/s41388-019-0947-7. Epub 2019 Aug 13.

3.

Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study.

Natale C, Leinwand GZ, Chiang J, Silberstein JL, Krane LS.

Clin Genitourin Cancer. 2019 Oct;17(5):380-388. doi: 10.1016/j.clgc.2019.06.010. Epub 2019 Jun 26.

PMID:
31395362
4.

Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.

Torquato S, Pallavajjala A, Goldstein A, Toro PV, Silberstein JL, Lee J, Nakazawa M, Waters I, Chu D, Shinn D, Groginski T, Hughes RM, Simons BW, Khan H, Feng Z, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Eisenberger MA, Antonarakis ES, Trock BJ, Park BH, Hurley PJ.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00227. Epub 2019 Apr 3.

5.

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, Chen Y, Silberstein JL, Kemeny G, Galletti G, Somarelli JA, Gupta S, Gregory SG, Scher HI, Dittamore R, Tagawa ST, Antonarakis ES, George DJ.

J Clin Oncol. 2019 May 1;37(13):1120-1129. doi: 10.1200/JCO.18.01731. Epub 2019 Mar 13.

PMID:
30865549
6.

Rethinking active surveillance for prostate cancer in African American men.

Leinwand GZ, Gabrielson AT, Krane LS, Silberstein JL.

Transl Androl Urol. 2018 Sep;7(Suppl 4):S397-S410. doi: 10.21037/tau.2018.06.19. Review.

7.

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.

Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19.

8.

Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men.

Waterhouse RL Jr, Van Neste L, Moses KA, Barnswell C, Silberstein JL, Jalkut M, Tutrone R, Sylora J, Anglade R, Murdock M, Shiffman Z, Vandenberg T, Shah N, Carter M, Krispin M, Groskopf J, Van Criekinge W.

Urology. 2019 Jun;128:62-65. doi: 10.1016/j.urology.2018.04.001. Epub 2018 Apr 13.

9.

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.

Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J.

Eur Urol. 2018 Aug;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035. Epub 2018 Feb 10.

10.

Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.

Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, Antonarakis ES.

Prostate. 2018 Apr;78(5):401-407. doi: 10.1002/pros.23484. Epub 2018 Jan 25.

11.

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR.

Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.

12.

A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men.

Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

J Urol. 2018 Jun;199(6):1459-1463. doi: 10.1016/j.juro.2017.11.113. Epub 2017 Dec 6.

PMID:
29223389
13.

Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.

Markowski MC, Silberstein JL, Eshleman JR, Eisenberger MA, Luo J, Antonarakis ES.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00127. Epub 2017 Oct 30.

14.

Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.

Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, Zhao P, De Marzo AM, Antonarakis ES, Wang M, Wu X, Luo Y, Su N, Nava Rodrigues D, Figueiredo I, Welti J, Park E, Ma XJ, Coleman I, Morrissey C, Plymate SR, Nelson PS, de Bono JS, Luo J.

Eur Urol. 2018 May;73(5):727-735. doi: 10.1016/j.eururo.2017.08.009. Epub 2017 Sep 1.

15.

Physical Model of Clear-Cell Renal Carcinoma With Inferior Vena Cava Extension Created From a 3-Dimensional Printer to Aid in Surgical Resection: A Case Report.

Libby RS, Silberstein JL.

Clin Genitourin Cancer. 2017 Oct;15(5):e867-e869. doi: 10.1016/j.clgc.2017.04.025. Epub 2017 Apr 26. No abstract available.

PMID:
28566203
16.

Racial Variation in the Outcome of Subsequent Prostate Biopsies in Men With an Initial Diagnosis of Atypical Small Acinar Proliferation.

Scott Libby R, Kramer JJ, Tue Nguyen HM, Feibus A, Thomas R, Silberstein JL.

Clin Genitourin Cancer. 2017 Dec;15(6):e995-e999. doi: 10.1016/j.clgc.2017.04.018. Epub 2017 Apr 26.

PMID:
28566201
17.

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J.

J Clin Oncol. 2017 Jul 1;35(19):2149-2156. doi: 10.1200/JCO.2016.70.1961. Epub 2017 Apr 6.

18.

Detection fidelity of AR mutations in plasma derived cell-free DNA.

Goldstein A, Toro PV, Lee J, Silberstein JL, Nakazawa M, Waters I, Cravero K, Chu D, Cochran RL, Kim M, Shinn D, Torquato S, Hughes RM, Pallavajjala A, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Trock BJ, Eisenberger MA, Antonarakis ES, Park BH, Hurley PJ.

Oncotarget. 2017 Feb 28;8(9):15651-15662. doi: 10.18632/oncotarget.14926.

19.

3D-printed soft-tissue physical models of renal malignancies for individualized surgical simulation: a feasibility study.

Maddox MM, Feibus A, Liu J, Wang J, Thomas R, Silberstein JL.

J Robot Surg. 2018 Mar;12(1):27-33. doi: 10.1007/s11701-017-0680-6. Epub 2017 Jan 20.

PMID:
28108975
20.

Identification of microRNA signature and potential pathway targets in prostate cancer.

Moustafa AA, Ziada M, Elshaikh A, Datta A, Kim H, Moroz K, Srivastav S, Thomas R, Silberstein JL, Moparty K, Salem FE, El-Habit OH, Abdel-Mageed AB.

Exp Biol Med (Maywood). 2017 Mar;242(5):536-546. doi: 10.1177/1535370216681554. Epub 2016 Dec 8.

21.

Racial Disparities in Histology and Short-Term Renal Functional Outcomes Following Robotic Nephron-Sparing Surgery.

Wang JC, Lai WR, Traore EJ, Liu J, Sholl AB, Mandava SH, Maddox MM, Mitchell GC, Viriyasiripong S, Silberstein JL, Kittles R, Lee BR.

Clin Genitourin Cancer. 2017 Apr;15(2):203-206. doi: 10.1016/j.clgc.2016.07.013. Epub 2016 Jul 22.

PMID:
27554583
22.

Racial variation in prostate needle biopsy templates directed anterior to the peripheral zone.

Feibus AH, Levy J, McCaslin IR, Doucet ME, Sholl AB, Moparty K, Thomas R, Sartor O, Silberstein JL.

Urol Oncol. 2016 Aug;34(8):336.e1-6. doi: 10.1016/j.urolonc.2016.03.017. Epub 2016 May 5.

PMID:
27155916
23.

Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy.

Feibus AH, Sartor O, Moparty K, Chagin K, Kattan MW, Ledet E, Levy J, Lee B, Thomas R, Silberstein JL.

J Urol. 2016 Oct;196(4):1053-60. doi: 10.1016/j.juro.2016.04.075. Epub 2016 Apr 29.

PMID:
27140073
24.

Accelerometer Measurement of Head Movement During Laparoscopic Surgery as a Tool to Evaluate Skill Development of Surgeons.

Viriyasiripong S, Lopez A, Mandava SH, Lai WR, Mitchell GC, Boonjindasup A, Powers MK, Silberstein JL, Lee BR.

J Surg Educ. 2016 Jul-Aug;73(4):589-94. doi: 10.1016/j.jsurg.2016.01.008. Epub 2016 Feb 26.

PMID:
26923103
25.

Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.

Silberstein JL, Taylor MN, Antonarakis ES.

Curr Urol Rep. 2016 Apr;17(4):29. doi: 10.1007/s11934-016-0584-4. Review.

26.

Electroencephalographic Monitoring of Brain Wave Activity During Laparoscopic Surgical Simulation to Measure Surgeon Concentration and Stress: Can the Student Become the Master?

Maddox MM, Lopez A, Mandava SH, Boonjindasup A, Viriyasiripong S, Silberstein JL, Lee BR.

J Endourol. 2015 Dec;29(12):1329-33. doi: 10.1089/end.2015.0239. Epub 2015 Oct 20.

PMID:
26414353
27.

Reply: To PMID 26099870.

Silberstein JL.

Urology. 2015 Jun;85(6):1262. doi: 10.1016/j.urology.2015.02.055. No abstract available.

PMID:
26099872
28.

Individualized Physical 3-dimensional Kidney Tumor Models Constructed From 3-dimensional Printers Result in Improved Trainee Anatomic Understanding.

Knoedler M, Feibus AH, Lange A, Maddox MM, Ledet E, Thomas R, Silberstein JL.

Urology. 2015 Jun;85(6):1257-61. doi: 10.1016/j.urology.2015.02.053.

PMID:
26099870
29.

Editorial comment from Dr Silberstein to Three-dimensional printing in urological surgery: what are the possibilities?

Silberstein JL.

Int J Urol. 2015 Apr;22(4):424-5. doi: 10.1111/iju.12743. Epub 2015 Mar 5. No abstract available.

30.

Significance and management of positive surgical margins at the time of radical prostatectomy.

Silberstein JL, Eastham JA.

Indian J Urol. 2014 Oct;30(4):423-8. doi: 10.4103/0970-1591.134240.

31.

Reply: To PMID 25283701.

Silberstein JL, Sartor OA.

Urology. 2014 Dec;84(6):1262. doi: 10.1016/j.urology.2014.06.066. Epub 2014 Oct 3. No abstract available.

PMID:
25283704
32.

Active surveillance of prostate cancer in African American men.

Silberstein JL, Feibus AH, Maddox MM, Abdel-Mageed AB, Moparty K, Thomas R, Sartor O.

Urology. 2014 Dec;84(6):1255-61. doi: 10.1016/j.urology.2014.06.064. Epub 2014 Oct 3. Review.

PMID:
25283702
33.

Testosterone and the Prostate.

Tan RB, Silberstein JL, Hellstrom WJ.

Sex Med Rev. 2014 Oct;2(3-4):112-120. doi: 10.1002/smrj.29. Epub 2015 Oct 19. Review.

PMID:
27784562
34.

Outcomes of retroperitoneal lymph node dissection for the most challenging cases.

Silberstein JL.

J Urol. 2014 Nov;192(5):1320-1. doi: 10.1016/j.juro.2014.08.058. Epub 2014 Aug 15. No abstract available.

PMID:
25130529
35.

Reply: To PMID 24962843.

Silberstein JL, Thomas R.

Urology. 2014 Aug;84(2):273. doi: 10.1016/j.urology.2014.03.048. Epub 2014 Jun 21. No abstract available.

PMID:
24962845
36.

Physical models of renal malignancies using standard cross-sectional imaging and 3-dimensional printers: a pilot study.

Silberstein JL, Maddox MM, Dorsey P, Feibus A, Thomas R, Lee BR.

Urology. 2014 Aug;84(2):268-72. doi: 10.1016/j.urology.2014.03.042. Epub 2014 Jun 21.

PMID:
24962843
37.

Impact of routine use of surgical drains on incidence of complications with robot-assisted radical prostatectomy.

Musser JE, Assel M, Guglielmetti GB, Pathak P, Silberstein JL, Sjoberg DD, Bernstein M, Laudone VP.

J Endourol. 2014 Nov;28(11):1333-7. doi: 10.1089/end.2014.0268. Epub 2014 Jul 24.

38.

Long-term survival of participants in the prostate cancer prevention trial.

Silberstein JL, Sartor O.

Asian J Androl. 2014 May-Jun;16(3):413-4. doi: 10.4103/1008-682X.122868. No abstract available.

39.

Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer.

Silberstein JL, Poon SA, Sjoberg DD, Maschino AC, Vickers AJ, Bernie A, Konety BR, Kelly WK, Eastham JA.

BJU Int. 2015 Jul;116(1):50-6. doi: 10.1111/bju.12676. Epub 2015 Apr 17.

40.

Intensity-modulated radiation therapy for prostate cancer.

Sartor O, Silberstein JL.

N Engl J Med. 2014 Feb 13;370(7):679. doi: 10.1056/NEJMc1314524. No abstract available.

PMID:
24521126
41.

Clinical outcomes of local and metastatic testicular sex cord-stromal tumors.

Silberstein JL, Bazzi WM, Vertosick E, Carver BS, Bosl GJ, Feldman DR, Bajorin DF, Motzer RJ, Al-Ahmadie H, Reuter VE, Sheinfeld J.

J Urol. 2014 Aug;192(2):415-9. doi: 10.1016/j.juro.2014.01.104. Epub 2014 Feb 8.

42.

Current clinical challenges in prostate cancer.

Silberstein JL, Pal SK, Lewis B, Sartor O.

Transl Androl Urol. 2013 Sep;2(3):122-36. doi: 10.3978/j.issn.2223-4683.2013.09.03. Review.

43.

Improving safety in robotic surgery: intraoperative crisis checklist.

Garg T, Bazzi WM, Silberstein JL, Abu-Rustum N, Leitao MM Jr, Laudone VP.

J Surg Oncol. 2013 Sep;108(3):139-40. doi: 10.1002/jso.23363. Epub 2013 Jun 18. No abstract available.

PMID:
23775871
44.

Endoscopic spray cryotherapy for genitourinary malignancies: safety and efficacy in a porcine model.

Power NE, Silberstein JL, Tarin T, Au J, Thorner D, Ezell P, Monette S, Fong Y, Rusch V, Finley D, Coleman JA.

Ther Adv Urol. 2013 Jun;5(3):135-41. doi: 10.1177/1756287212465457.

45.

Words of wisdom. Re: Radical prostatectomy versus observation for localized prostate cancer.

Silberstein JL, Eastham JA.

Eur Urol. 2013 Jun;63(6):1130-1. doi: 10.1016/j.eururo.2013.03.020. No abstract available.

PMID:
23608081
46.

Neutrophil gelatinase-associated lipocalin (NGAL) levels in response to unilateral renal ischaemia in a novel pilot two-kidney porcine model.

Silberstein JL, Sprenkle PC, Su D, Power NE, Tarin TV, Ezell P, Sjoberg DD, Feifer A, Fleisher M, Russo P, Touijer KA.

BJU Int. 2013 Aug;112(4):517-25. doi: 10.1111/bju.12066. Epub 2013 Mar 19.

47.

Trends in partial and radical nephrectomy: an analysis of case logs from certifying urologists.

Poon SA, Silberstein JL, Chen LY, Ehdaie B, Kim PH, Russo P.

J Urol. 2013 Aug;190(2):464-9. doi: 10.1016/j.juro.2013.02.094. Epub 2013 Feb 27.

48.

Is laparoscopic partial nephrectomy already the gold standard for small renal masses?.

Power NE, Silberstein JL, Touijer K.

Arch Esp Urol. 2013 Jan-Feb;66(1):90-8. Review.

PMID:
23406804
49.

Lower urinary tract symptoms, benign prostatic hyperplasia, and prostate cancer: seek and ye shall find.

Silberstein JL, Eastham JA.

Eur Urol. 2013 Jun;63(6):1028-9; discussion 1030. doi: 10.1016/j.eururo.2013.01.019. Epub 2013 Jan 29. No abstract available.

PMID:
23375431
50.

A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons.

Silberstein JL, Su D, Glickman L, Kent M, Keren-Paz G, Vickers AJ, Coleman JA, Eastham JA, Scardino PT, Laudone VP.

BJU Int. 2013 Feb;111(2):206-12. doi: 10.1111/j.1464-410X.2012.11638.x.

Supplemental Content

Loading ...
Support Center